Insulet Corp PODD
We take great care to ensure that the data presented and summarized in this overview for INSULET CORP is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding PODD
View all-
Vanguard Group Inc Valley Forge, PA8.47MShares$2.26 Billion0.04% of portfolio
-
Capital Research Global Investors Los Angeles, CA7.77MShares$2.07 Billion0.39% of portfolio
-
Black Rock Inc. New York, NY6.06MShares$1.62 Billion0.03% of portfolio
-
State Street Corp Boston, MA2.91MShares$777 Million0.03% of portfolio
-
Baillie Gifford & CO2.28MShares$607 Million0.4% of portfolio
-
Geode Capital Management, LLC Boston, MA1.74MShares$463 Million0.03% of portfolio
-
Clearbridge Investments, LLC New York, NY1.47MShares$392 Million0.28% of portfolio
-
Fil LTD Hamilton, D01.44MShares$384 Million0.33% of portfolio
-
Ameriprise Financial Inc Minneapolis, MN1.36MShares$363 Million0.08% of portfolio
-
Morgan Stanley New York, NY1.21MShares$322 Million0.02% of portfolio
Latest Institutional Activity in PODD
Top Purchases
Top Sells
About PODD
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Insider Transactions at PODD
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Nov 12
2024
|
Luciana Borio Director |
SELL
Open market or private sale
|
Direct |
508
-15.4%
|
$139,192
$274.8 P/Share
|
Sep 11
2024
|
Jessica Hopfield Director |
SELL
Open market or private sale
|
Direct |
7,628
-22.08%
|
$1,716,300
$225.26 P/Share
|
Sep 11
2024
|
Jessica Hopfield Director |
BUY
Exercise of conversion of derivative security
|
Direct |
7,628
+18.09%
|
$221,212
$29.87 P/Share
|
Sep 10
2024
|
Timothy J Scannell Director |
SELL
Open market or private sale
|
Direct |
5,000
-14.05%
|
$1,125,000
$225.84 P/Share
|
Sep 09
2024
|
Lauren Budden Group VP, CAO and Controller |
SELL
Open market or private sale
|
Direct |
1,506
-18.56%
|
$332,826
$221.41 P/Share
|
Sep 09
2024
|
Mark N Field SVP & Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
1,383
-12.41%
|
$304,260
$220.87 P/Share
|
Aug 30
2024
|
Prem Singh SVP, Global Operations |
SELL
Open market or private sale
|
Direct |
1,824
-33.28%
|
$368,448
$202.27 P/Share
|
Aug 30
2024
|
Mark N Field SVP & Chief Technology Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
203
-1.79%
|
$41,006
$202.77 P/Share
|
Aug 29
2024
|
Ana Maria Chadwick EVP, CFO & Treasurer |
BUY
Open market or private purchase
|
Direct |
100
+0.75%
|
$20,600
$206.0 P/Share
|
Aug 28
2024
|
Mark N Field SVP & Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
1,387
-10.89%
|
$281,561
$203.0 P/Share
|
Jun 28
2024
|
Mark N Field SVP & Chief Technology Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
141
-1.1%
|
$28,341
$201.8 P/Share
|
Jun 14
2024
|
Mark N Field SVP & Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
1,500
-10.43%
|
$298,500
$199.96 P/Share
|
Jun 10
2024
|
Mark N Field SVP & Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
2,131
-12.91%
|
$404,890
$190.43 P/Share
|
Jun 10
2024
|
Timothy J Scannell Director |
SELL
Open market or private sale
|
Direct |
7,000
-16.44%
|
$1,330,000
$190.51 P/Share
|
Jun 04
2024
|
Michael R Minogue Director |
BUY
Bona fide gift
|
Indirect |
843
+15.45%
|
-
|
Jun 04
2024
|
Michael R Minogue Director |
SELL
Bona fide gift
|
Direct |
843
-37.92%
|
-
|
Jun 04
2024
|
Luciana Borio Director |
SELL
Open market or private sale
|
Direct |
360
-9.84%
|
$65,520
$182.58 P/Share
|
May 31
2024
|
James Hollingshead President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,973
-8.72%
|
$703,221
$177.19 P/Share
|
May 28
2024
|
Timothy J Scannell Director |
SELL
Open market or private sale
|
Direct |
3,300
-7.19%
|
$594,000
$180.9 P/Share
|
May 28
2024
|
Timothy J Scannell Director |
BUY
Exercise of conversion of derivative security
|
Direct |
18,267
+10.57%
|
$602,811
$33.31 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 64.9K shares |
---|---|
Bona fide gift | 843 shares |
Exercise of conversion of derivative security | 37.5K shares |
Open market or private purchase | 100 shares |
Bona fide gift | 12K shares |
---|---|
Open market or private sale | 45.2K shares |
Payment of exercise price or tax liability | 9.5K shares |